Thierry Chauche
Director of Finance/CFO at SAGIMET BIOSCIENCES INC.
Thierry Chauche active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SAGIMET BIOSCIENCES INC. | Comptroller/Controller/Auditor | 05/05/2024 | - |
| Director of Finance/CFO | 05/05/2024 | - |
Career history of Thierry Chauche
Former positions of Thierry Chauche
| Companies | Position | Start | End |
|---|---|---|---|
| PROVENTION BIO, INC. | Director of Finance/CFO | 30/11/2021 | 31/03/2023 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 29/02/2020 | 31/12/2020 |
Training of Thierry Chauche
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| école Des Ponts Paristec | Graduate Degree |
Statistics
International
| United States | 5 |
| France | 2 |
Operational
| Director of Finance/CFO | 2 |
| Masters Business Admin | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SAGIMET BIOSCIENCES INC. | Health Technology |
| Private companies | 2 |
|---|---|
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Thierry Chauche
- Experience